Astroglial Plasticity Is Implicated in Hippocampal Remodelling in Adult Rats Exposed to Antenatal Dexamethasone. by Shende, VH et al.
Astroglial Plasticity Is Implicated in Hippocampal Remodelling in Adult
Rats Exposed to Antenatal Dexamethasone.
Shende, VH; McArthur, S; Gillies, GE; Opacka-Juffry, J
 
 
 
 
 
© 2015 Vishvesh H. Shende et al.
CC-BY
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/18821
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
Research Article
Astroglial Plasticity Is Implicated in Hippocampal Remodelling
in Adult Rats Exposed to Antenatal Dexamethasone
Vishvesh H. Shende,1 Simon McArthur,2,3 Glenda E. Gillies,2 and Jolanta Opacka-Juffry1
1Department of Life Sciences, University of Roehampton, London SW15 4JD, UK
2Division of Experimental Medicine, Imperial College, London W12 0NN, UK
3Department of Biomedical Sciences, Faculty of Science & Technology, University of Westminster, London W1W 6UW, UK
Correspondence should be addressed to Jolanta Opacka-Juffry; j.opacka-juffry@roehampton.ac.uk
Received 5 December 2014; Accepted 4 February 2015
Academic Editor: Anna Dunaevsky
Copyright © 2015 Vishvesh H. Shende et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The long-term effects of antenatal dexamethasone treatment on brain remodelling in 3-month-old male Sprague Dawley rats
whose mothers had been treated with dexamethasone were investigated in the present study. Dorsal hippocampus, basolateral
amygdala and nucleus accumbens volume, cell numbers, and GFAP-immunoreactive astroglial cell morphology were analysed
using stereology. Total brain volume as assessed by micro-CT was not affected by the treatment. The relative volume of the dorsal
hippocampus (% of total brain volume) showed a moderate, by 8%, but significant reduction in dexamethasone-treated versus
control animals. Dexamethasone had no effect on the total and GFAP-positive cell numbers in the hippocampal subregions,
basolateral amygdala, and nucleus accumbens. Morphological analysis indicated that numbers of astroglial primary processes were
not affected in any of the hippocampal subregions analysed but significant reductions in the total primary process length were
observed in CA1 by 32%, CA3 by 50%, and DG by 25%. Mean primary process length values were also significantly decreased in
CA1 by 25%, CA3 by 45%, and DG by 25%. No significant astroglial morphological changes were found in basolateral amygdala
and nucleus accumbens. We propose that the dexamethasone-dependent impoverishment of hippocampal astroglial morphology
is the case of maladaptive glial plasticity induced prenatally.
1. Introduction
Astroglia have been acknowledged to play a role in brain
responses to stress and glucocorticoids as its chemical medi-
ators [1, 2]. Such effects implicate brain plasticity and can
lead to regional brain remodelling, with volume changes
observed within the limbic system in cases of long-term
“toxic” stress, and depression and depression-like conditions
in humans and animals, respectively [1, 3]. Thus increased
amygdala volumes have been observed in teenage adoptees
who experienced early life deprivation [4]. On the other
hand, hippocampal volume reductions have been reported
in patients with PTSD and major depressive disorder with
history of early life deprivation [5]. Stress-related reductions
in hippocampal volume have also been observed in experi-
mental animals, both rodents [6, 7] and nonhuman primates
[8]. Hippocampal volume losses, albeit usually of modest
degree, indicate changes in brain tissue architecture, with
most studies reporting on neuroplastic rearrangements [9].
However, there is also evidence of astroglial involvement in
hippocampal remodelling observed in the rat model of early
life deprivation [7].
Also prenatal stress can result in a reduced hippocampal
volume associated with suppressed neurogenesis in rhesus
monkeys, a phenomenon found to be mediated by corticos-
teroids [10]. Antenatal treatment with synthetic steroids such
as dexamethasone, which cross the placenta [11], is often used
in pregnant women at risk for preterm birth [12]. It can, how-
ever, affect neurobehavioural development of children who
have lower IQ scores and poormotor and visual coordination
skills during their school age [13]. About 85%of neonateswith
antenatal corticosteroid therapy receivemultiple courses [14],
and dexamethasone is commonly administered to ventilator-
dependent premature infants with chronic lung insufficiency
to improve lung function [15, 16].
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The first human study on postmortem hippocampi of
neonates who had been antenatally treated with dexametha-
sone or betamethasone has shown a glucocorticoid-related
reduced density of neurons; no differences have been found in
gliosis or myelination [17]. Experimental studies on animals
confirmnegative effects of antenatal glucocorticoid treatment
(AGT) on hippocampal neurogenesis [18]; however, there
are no reports about AGT effects on brain glia. The present
study addressed this gap in knowledge and hypothesised that
rat hippocampal astroglia respond to AGT in a maladaptive
manner, in the long term.
2. Experimental Procedures
2.1. Animals. All animal procedures were carried out in
accordance with the United Kingdom Animals Scientific
Procedures Act of 1986, at Imperial College London. Sprague
Dawley rats (Harlan Olac, Blackthorn, Bicester, Oxfordshire,
UK) were kept under controlled lighting (on 0800–2000 h),
temperature (21–23∘C), and humidity (63%), with standard
rat chow and drinking water (except as described below) pro-
vided ad libitum. Male and female rats were caged separately
and allowed to acclimatize to their new environment for one
week, after which groups of one male and two female rats
were housed together overnight and the presence of vaginal
plugs the following morning was taken to confirm mating;
pregnancy was confirmed approximately 6 days later by
palpation.The timed pregnant rats were housed five per cage
until gestational day (GD) 15, when they were caged singly
in preparation for giving birth. From GD 19/20 pregnant rats
were monitored several times a day and the day of birth
was defined as day 0. No more than two progenies per litter
(one male, one female) were included in each experimental
group in order to minimize potential effects of litter-of-
origin. Offspring were weaned at three weeks; male and
female progenywere housed separately and theywere allowed
to grow to adulthood with no further interventions other
than normal husbandry. At 68 ± 2 days of age animals were
decapitated between 0900 and 1000 h. Male rats were used in
the present study.
2.2. Dexamethasone Treatment. Dexamethasone was admin-
istered noninvasively as dexamethasone sodium phosphate
(Faulding Pharmaceuticals Plc., Royal Leamington Spa, UK)
in the drinking water given to pregnant rats at GD 16–19, at
the dose of 0.5 𝜇g/mL [19] with an estimated daily intake of
approximately 75𝜇g/kg [20].Withdrawing dexamethasone at
GD 19 allowed for clearance of the steroid from the maternal
circulation prior to birth, with no observable effects on the
outcomes of pregnancy, maternal behaviour, or adult body
weight of the offspring [19–21].
2.3. pQCT Scanning. Total frozen brain volume (𝑛 = 6 per
group) was analysed by means of peripheral quantitative
computed tomography (pQCT) on a Stratec Research SA+
scanner (Stratec Medizintechnik, Pforzheim, Germany) as
described elsewhere [7]. Serial coronal CT scans were per-
formed covering entire brain region. Further analysis to
measure total brain volume was carried out by using software
Avizo (version 5; Mercury Computer Systems, Chelmsford,
MA, USA).
2.4. Brain Tissue Preparation. Frozen coronal sections
(25 𝜇m) were cut in an anterior-posterior direction. The
sectioning procedure was designed to yield the following
regions of interest (ROIs) (in brackets A/P coordinates from
bregma, in mm): nucleus accumbens core (3.00 to 2.16),
basolateral amygdala (−1.72 to −2.28) and dorsal hippo-
campus (−2.04 to −4.68) according to the rat brain atlas by
Paxinos and Watson [22].
2.5. Total Cell Count. Brain sections were stained with hema-
toxylin (HX) for total cell count and then gradually dehy-
drated, air-dried, and protected with a histological mounting
medium and covered with cover slips.
2.6. Immunohistochemistry. To visualise astrocytes, glial fib-
rillary acidic protein (GFAP) immunohistochemistry was
performed [23]. Briefly, peroxidase inactivation was carried
out in PBS with 20% methanol, 1.5% H
2
O
2
, and 0.3%
Triton X-100; blocking medium contained 0.1% Triton X-
100 and 10% normal horse serum, and the anti-GFAP pri-
mary antibody (Sigma, UK) was diluted 1 : 500 and applied
overnight at 4∘C. Controls (blanks) without the primary
antibody were processed in parallel. All sections were incu-
bated with the secondary antibody and streptavidin-biotin-
peroxidase complex according to manufacturer’s instruc-
tion (ABC kit, Vector Laboratories, UK). Sections were
treated with 3,3󸀠-diaminobenzidine (5mg/mL, 0.01% H
2
O
2
),
rinsed, dehydrated, and mounted in xylene-based Histo-
mount (BDH/Merck, Poole, UK) prior to stereology.
2.7. Stereological Procedures
2.7.1. Volume Analysis. Volume estimation using the Cava-
lieri principle was performed with Stereo-Investigator soft-
ware (Version 9, MicroBrightField, Inc., Germany) and
Olympus BX51 microscope fitted with a motorized stage and
video camera on a Zeiss UPlan FLN with a 4x objective
(NA = 0.25). Starting at a random position, every tenth
section was analyzed, leading to an average of 12 sections for
dorsal hippocampus, 6 sections for basolateral amygdala, and
5 sections for nucleus accumbens, per brain. These sets of
consecutive sections were used for the estimation of volumes
for both control and test groups. The investigator was blind
to the experimental groups. A point counting grid (PCG)
(i.e., 𝑑 = 50 𝜇m) was used for volume estimation to obtain
maximum efficiency. Representative area per point (𝑎/𝑝)was
2500 𝜇m2. After applying the PCG on the sampled sections
in a systematic randommanner, the number of points hitting
region of interest was counted (Figure 1(a)). The efficiency of
sampling and volume estimation were checked by estimation
of coefficient of error and coefficient of variation [24].
2.7.2. Cell Counts. Cells in the dorsal hippocampal subre-
gions (CA1, CA2, CA3, and DG), basolateral amygdala, and
nucleus accumbens were counted using the optical fraction-
ator (Stereo-Investigator, Version 9, MicroBrightField Inc.,
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(a) (b)
Control
(c)
Dex-treated
(d)
Figure 1: Dorsal hippocampal volume, HX stain (a) and GFAP-positive astroglial cell count (b) estimated by means of stereology. Changes
in astroglial morphology in response to AGT: GFAP-positive astroglial cells in control (c) and Dex-treated (d) male rats (dorsal hippocampal
dentate gyrus area). GFAP-positive primary process length is reduced in Dex-treated male rats when compared with control, (d) versus (c).
Astroglial processes observed at 100x magnification.
Germany). An unbiased estimation of total number of cells
was achieved by choosing every 10th section according to the
systematic random sampling procedure [24] yielding 8 sec-
tions per animal. A pilot study was undertaken to determine
the following parameters. A sampling area of 160/2500𝜇m2
was found to be optimal for this study. Dissector height was
8 𝜇m and a 1 𝜇m guard zone at the top and bottom part of the
section was excluded from the analysis at every step. A fixed
counting frame of 50 × 50 and a variable sampling grid size
(𝑥-𝑦-axis) of 150 × 150 CA1, 150 × 150 CA2, 300 × 300 CA3,
and 300 × 300 DG were used for the dorsal hippocampus
(Figure 1(b)) and 150 × 150 was used for both basolateral
amygdala and nucleus accumbens. These sampling grids
resulted in 100–200 counting sites per brain. HX and GFAP-
positive cells were counted using a 100x Nicon UPlan FLN
objective (NA = 1.30) which allowed accurate recognition.
Each cell was counted according to the unbiased counting
rules. The efficiency of convenient number of sampled cells
and parameters was checked by estimation of coefficient of
error (CE) and coefficient of variation (CV) [24].
2.7.3. AstroglialMorphology. Morphological analysiswas per-
formed on 80 astrocytes in each brain (10 astrocytes per
section) usingNeurolucida software (Version 9,MicroBright-
Field, Inc., Germany) for tracing boundaries of the ROIs
and astrocytes. Astrocytes within the ROI were traced in
a systematic random manner, taking care to avoid those
which were superimposed upon other astrocytes or blood
vessels. The traced astrocytes were then analysed using
Neurolucida explorer software (Version 9, MicroBrightField,
Inc., Germany). Morphological analysis was performed by
observer who was blind to the experimental groups. Primary
process length was measured using 100x objective (Nicon
UPlan FLN, NA = 1.30) and by counting the primary pro-
cesses extending directly from the soma in both the lateral
and central quadrants of astrocytes in the same sections.
2.8. Statistical Analysis. Using SPSS 17.0 statistical software
(SPSS, Inc., USA), ANOVA with a post hoc Tukey test was
performed, comparing between group differences. Indepen-
dent 𝑡-test was performed tomeasure difference between two
groups. Statistical significance was set at 𝑃 < 0.05.The results
are expressed as mean ± SEM.
3. Results
3.1. Whole Brain Volume and Brain Weight. No significant
effects of AGT were observed in the whole brain volume
(𝑃 = 0.376) and brain weight (𝑃 = 0.442) (Table 1).
3.2. VolumeAnalyses. AGT rats showed a significant decrease
in the absolute volume of dorsal hippocampus by 6.5%
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Table 1: Effects of AGT exposure on brain weight and volume of
male adult Sprague Dawley rats.
Control Dex-treated
Brain weight (g) 1.74 ± 0.02 1.77 ± 0.03
Brain volume (mm3) 1650.18 ± 17.75 1681.24 ± 28.43
The brain weight and volume are expressed as mean ± SEM (𝑛 = 6 per
group). No significant differences between Dex-treated (AGT) and control
were observed.
Table 2: Effects of AGT on the regional brain volume of male adult
Sprague Dawley rats.
Volume
Control Dex-treated
Absolute values (mm3)
Dorsal hippocampus 32.8 ± 0.46 30.8 ± 0.50∗
Basolateral amygdala 0.81 ± 0.02 0.80 ± 0.02
Nucleus accumbens 2.28 ± 0.06 2.26 ± 0.07
Relative values (as % brain volume)
Dorsal hippocampus 1.99 ± 0.04 1.83 ± 0.04∗
Basolateral amygdala 0.046 ± 0.001 0.048 ± 0.001
Nucleus accumbens 0.138 ± 0.004 0.135 ± 0.005
The volume of the dorsal hippocampus, basolateral amygdala, and nucleus
in control and dexamethasone-treated groups (𝑛 = 6 per group). Data are
expressed as mean ± SEM. ∗𝑃 < 0.05 versus control, independent sample 𝑡-
test.
versus control (𝑃 < 0.05). When expressed as percentage
of the whole brain volume, the volume reduction was 8%
(𝑃 < 0.05) versus control. No significant differences were
observed between the treatment groups in the basolateral
amygdala (𝑃 = 0.834) and nucleus accumbens (𝑃 = 0.905)
(Table 2).
3.3. HX Stained Total Cell Numbers. AGT did not affect the
total cell count (HX stain) in the dorsal hippocampal subre-
gions CA1 (𝑃 = 0.821), CA2 (𝑃 = 0.975), CA3 (𝑃 = 0.991),
and DG (𝑃 = 0.959), basolateral amygdala (𝑃 = 0.180), and
the nucleus accumbens (𝑃 = 0.474) (Table 3).
3.4. GFAP-Positive Astroglial Cell Numbers. There were no
significant AGT effects on GFAP-positive cell numbers in the
dorsal hippocampal subregions CA1 (𝑃 = 0.607), CA2 (𝑃 =
0.517), CA3 (𝑃 = 0.500), and DG (𝑃 = 0.424), basolateral
amygdala (𝑃 = 0.495), and the nucleus accumbens (𝑃 =
0.384) (Table 4).
3.5. Astroglia (GFAP-Positive) Cell Morphology. AGT did
not affect the numbers of primary processes in the region
analysed (Tables 5 and 6) and it had no significant effects
on the astroglial morphology in the nonhippocampal regions
(Table 5, all group differences at 𝑃 < 0.05).
However, AGT affected the length of primary processes
in GFAP-positive cells within the hippocampus (Figures 1(a)
and 1(b)); it led to a significant reduction in the total length of
astrocytic primary processes in the hippocampal subregions:
by 32% in CA1 (𝑃 < 0.05), 50% in CA3 (𝑃 < 0.001), and by
Table 3: Effects of AGT on the number of total (hematoxylin-
stained) and GFAP-positive cellsin dorsal hippocampus of male
adult Sprague Dawley rats.
Subregion Control Dex-treated
Hematoxylin stained cell numbers estimated per region (×103)
CA1 706.8 ± 8.8 714.1 ± 29.7
CA2 95.9 ± 3.4 95.8 ± 2
CA3 491.3 ± 37.2 490.7 ± 32.6
DG 791.4 ± 31.6 789.1 ± 30.6
GFAP +ve cell numbers estimated per region (×103)
CA1 219.4 ± 6 213.6 ± 9.1
CA2 26.8 ± 1.1 25.8 ± 1
CA3 110.9 ± 6.1 104.4 ± 6.9
DG 201 ± 4.7 195.3 ± 5.1
The numbers of total and GFAP-positive cells are shown for control and
dexamethasone-treated groups (𝑛 = 6 per group). Data are expressed as
mean ± SEM. No significant differences between Dex-treated (AGT) and
control were observed.
Table 4: Effects of AGT on the number of total and GFAP-positive
cells in basolateral amygdala and nucleus accumbens region of cells
in male adult Sprague Dawley rats.
Subregion Control Dex-treated
Hematoxylin stained cell numbers estimated per region (×103)
Basolateral amygdala 52.86 ± 3.4 58.79 ± 2.4
Nucleus accumbens 146.58 ± 6.8 139.61 ± 6.4
GFAP +ve cell numbers estimated per region (×103)
Basolateral amygdala 23.68 ± 1.9 25.71 ± 2.1
Nucleus accumbens 20.73 ± 1.8 18.28 ± 2.0
Thenumbers of total andGFAP-positive cells in control and dexamethasone-
treated groups (𝑛 = 6 per group). Data are expressed as mean ± SEM.
No significant differences between Dex-treated (AGT) and control were
observed.
Table 5: Effects of AGT on themorphology of GFAP-positive astro-
glia in the basolateral amygdala and nucleus accumbens region of
male adult Sprague Dawley rats.
GFAP-astroglia morphology
Control Dex-treated
Total primary process length (𝜇m)
Basolateral amygdala 5761.8 ± 582.6 6123.5 ± 598.9
Nucleus accumbens 4033.4 ± 403.9 3890.1 ± 489.2
Primary process mean length
Basolateral amygdala 26.8 ± 1.6 27.5 ± 2.1
Nucleus accumbens 22.7 ± 1.8 20.8 ± 1.7
Number of primary processes
Basolateral amygdala 213 ± 11.4 221 ± 9.1
Nucleus accumbens 178 ± 8.5 185 ± 10.6
The total primary process length, mean primary process length, and num-
bers of primary processes of GFAP-positive cells in control and dexametha-
sone-treated groups (𝑛 = 6 per group). Data are expressed as mean ± SEM.
No significant differences between Dex-treated (AGT) and control were
observed.
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Table 6: Effects of AGT on GFAP-positive astroglial primary
process numbers in male adult Sprague Dawley rats.
GFAP-astroglia morphology
Control Dex-treated
Number of primary process
CA1 362 ± 36.1 323.3 ± 4.4
CA2 301 ± 26.2 311 ± 26.4
CA3 339 ± 16.9 305.7 ± 8.1
DG 321.7 ± 14.3 314.8 ± 4.7
The numbers of primary processes of GFAP-positive cells in control and
dexamethasone-treated groups (𝑛= 6 per group). Data are expressed asmean
± SEM. No significant differences between Dex-treated (AGT) and control
were observed.
25% in DG (𝑃 < 0.01) (Figure 2). AGT-dependent changes
were also observed in the mean length of astrocytic primary
processes: reductions by 25% in CA1 (𝑃 < 0.01), 45% in CA3,
(𝑃 < 0.001), and 25% in DG (𝑃 < 0.01) (Figure 3).
4. Discussion
The present study was focused on the effects of AGT on
central astroglia and regional volume of the hippocampus,
amygdala, and nucleus accumbens as the areas of the limbic
system implicated in response to stress and corticosteroids [2,
3, 9]. AGTwas administered to pregnant dams noninvasively,
through drinkingwater, to avoid the stress of animal handling
and injections. Of the brain areas tested in adult male rats, the
hippocampus responded to AGT, with a long-term reduction
in its volume and changes in astroglial morphology. It is plau-
sible that the observed impoverishment of astrocytic primary
branches underpins the hippocampal volume reduction as
we found no evidence of cell loss. To our knowledge, such
AGT-dependent long-term hippocampal remodelling with
implications for astroglia has not been reported before.
Astroglia were visualised by means of the commonly
used GFAP immunohistochemistry. GFAP is an intermediate
filament protein present in cell bodies and primary branches
although fine distal processes show little or no GFAP [25].
Although GFAP staining is selective to astrocytes, it does not
label all astrocytes in the brain. Accepting these limitations
of GFAP immunohistochemistry, the present study focused
on the length and numbers of primary astrocytic processes
where GFAP is reliably detectable [25]. Stereology was our
method of choice as it offers an unbiased approach to regional
brain volumetry and morphometry [24].
Previous volumetric studies have considered specific
brain regions, expressing their volumes in absolute terms
with no reference to the total brain volume, which itself is
a variable. Thus the present application of pQCT to measure
total brain volume adds the much needed rigour to volu-
metric assessment where regional volumes need to be scaled
to the total brain volume. This is particularly important as
perinatal corticosteroid exposure can lead to a decrease in
brain weight/volume. For example, a significant brain weight
reduction has been reported in rhesus monkeys treated
prenatally with corticosteroids [26] and repeated doses of
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Figure 2: Effect of prenatal dexamethasone treatment on the total
length of primary astrocytic processes in hippocampal subregions
of male adult Sprague Dawley rats. The total primary process length
ofGFAP-positive cells in control and dexamethasone-treated groups
(𝑛 = 6 per group). Data are expressed as mean ± SEM. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 versus control, independent sample
𝑡-test.
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Figure 3: Effect of prenatal dexamethasone treatment on the mean
length of primary astrocytic processes in hippocampal subregions of
male adult Sprague Dawley rats. The mean primary process length
ofGFAP-positive cells in control and dexamethasone-treated groups
(𝑛 = 6 per group). Data are expressed as mean ± SEM. ∗∗𝑃 < 0.01
and ∗∗∗𝑃 < 0.001 versus control, independent sample 𝑡-test.
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dexamethasone at E17–19 have resulted in a significant brain
weight reduction in newborn rats [27]. The present study
found no AGT effects on the whole brain weight and volume,
the latter measured by pQCT. One of the factors which affect
the brain weight and volume is the amount of corticosteroid
administered. In the present study a relatively small dose
was given which, as discussed previously [19], is in the range
used in perinatal medicine and mimics the glucocorticoid
activity that is required for normal lung maturation during
late gestation.
Within the developing brain, the limbic system, richly
expressing glucocorticoid and mineralocorticoid receptors
[28], is sensitive to the endogenous and exogenous corti-
costeroids, which can affect these brain areas with long-
term consequences for their structure and function [29].
Reductions in the regional brain volume of the hippocampus
and amygdala have been reported in preterm infants [30–
32] and a cortical brain volume reduction of 35% has been
observed in premature infants treated with dexamethasone
[33]. On the other hand, there have been reports of no effect
of single betamethasone antenatal dose on regional brain
volumes, particularly within the limbic system [34].
In the present study, the hippocampus was significantly
affected by AGT, in line with the theory that this region
develops primarily during the foetal period [35] although
hippocampal volume losses have also been observed fol-
lowing administration of corticosteroids in adult monkeys
and rats [36, 37]. No changes were seen in the basolateral
amygdala and nucleus accumbens volume, which suggests a
region-selective treatment effect consistent with the density
of glucocorticoid receptor distribution [28].
A transient reduction in hippocampal volume has been
observed in adolescent but not adult mice exposed to a clin-
ically relevant dose of dexamethasone at E15 [18]. The extent
of hippocampal volume loss is normally mild/moderate. The
present reduction of the hippocampal volume by 8% fits in
that range while being statistically significant. It is compara-
ble with some previous reports on stress/steroid-dependent
losses in the hippocampal volume across several species.Thus
Coe et al. [10] have found hippocampal volume reductions by
12% and 10% in the offspring of rhesus monkeys exposed to
early life stress. In tree shrews, four weeks’ cortisol treatment
or psychosocial stress has resulted in a hippocampal volume
loss by 5–10% [38]. Chronic social defeat stress has led to
a similarly mild yet significant hippocampal volume loss
in adult rats [6]. Human adolescents who were born very
preterm have been found to have a hippocampal volume loss
in the range of 12% to 15.6% [39].
What causes the hippocampal volume losses in responses
to stress/glucocorticoids? There is a range of factors such as
neuronal and/or glial cell death, reduction of cell size, includ-
ing atrophy of neuronal dendrites and/or glial branches,
reduced water content or impaired neurogenesis [1], and/or
reduced microvasculature [6]. The present study did not find
cell losses in the brain areas tested and focused on astroglia
because of their major role in maintaining brain plasticity
at the level of synapses and cells [25]. Currently, published
studies on the mechanisms underlying glucocorticoid-
induced brain volume reductions have focused on neurons.
As a result, neuronal cell loss has been well researched and
documented, and various dexamethasone treatments have
been found to lead to neuronal loss in rats [40, 41] and pri-
mates [26, 37] mostly in the hippocampal CA3 and dentate
gyrus. Less attention has been given to astroglial cells, despite
their role in the maintenance of brain homeostasis and
plasticity [25].
The impoverishment in astroglial morphology reported
in the present study is consistent with the known glia-
inhibitory effects of exogenous glucocorticoids or stress in
vitro [42, 43] and in vivo [44]. Treatment with corticosterone
or synthetic glucocorticoids such as dexamethasone has been
known to inhibit GFAP expression in the neonatal and
adult rat brain [45–48] thus suggesting that astrocytes can
be affected by glucocorticoid overload. The very fact that
dexamethasone can affect GFAP expression raises a valid
methodological consideration as to what extent the present
observations of changes in the morphology of GFAP-positive
astroglia are affected bymethodological biaswhen comparing
between the groups. Central astroglia are heterogeneous
[25, 49] and using GFAP as the only immunohistochemical
marker brings in an intrinsic limitation, shared by many cur-
rent studies, as critically reviewed elsewhere [49]. However,
the present GFAP responses to AGT appear to be selective to
the hippocampus, where astroglial primary branches reduced
in length but no GFAP-positive cell losses were found. Such
a discrete response of GFAP immunoreactivity implies that
dexamethasone, administered at the present lowdose asAGT,
did not induce a global effect in GFAP expression. This
not only highlights the unique susceptibility of hippocampal
regions but also suggests that the changes observed here are
true manifestations of impoverished hippocampal astroglial
morphology in response to AGT.
It is increasingly evident that nongenetic/environmental
factors acting in early life result in long-term alterations of
the physiological systems affected. Perinatal programming
and/or plasticity of the physiological system under extreme
conditions such as “toxic” stress or AGT can result in long-
term neurobehavioural abnormalities [3, 29, 50] and there is
growing evidence that prenatal or early postnatal exposure to
stressors affects the long-term brain functioning [51].
To conclude, this study reports significant maladaptive
changes in astroglia in the hippocampal subregions CA1, CA3
and dentate gyrus, as a long-term effect of AGT. It is plausible
to assume that the reductions in astrocytic primary branches
contribute to the losses in the hippocampal volume. They
are also likely to affect astroglial function and neuron-glia
interactions as retraction of primary astroglial processes can
disadvantage local networks formed with glia and neurons.
The observed dexamethasone-induced impoverishment of
astroglial morphology can be treated as a demonstration of
glial maladaptive plasticity, a phenomenon that deserves
more research in the context of effects of corticosteroid
overload and stress-related pathologies. Epigenetics of this
phenomenon should be of interest considering the clinical
use of dexamethasone.
Neural Plasticity 7
Abbreviations
AGT: Antenatal glucocorticoid treatment
Dex: Dexamethasone
GD: Gestational day
GFAP: Glial fibrillary acidic protein
HX: Hematoxylin
MDD: Major depressive disorder
PBS: Phosphate-buffered saline
PTSD: Posttraumatic stress disorder
ROI: Region of interest.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This work was supported by the Wellcome Trust Grant (no.
086871/Z/08/Z) to G. E. Gillies. Vishvesh H. Shende was a
Ph.D. student sponsored by the University of Roehampton.
The authors thank Dr. Todd Rae (Roehampton) for training
Vishvesh H. Shende in the pQCT technique.
References
[1] B. Cze´h and P. J. Lucassen, “What causes the hippocampal
volume decrease in depression? Are neurogenesis, glial changes
and apoptosis implicated?” European Archives of Psychiatry and
Clinical Neuroscience, vol. 257, no. 5, pp. 250–260, 2007.
[2] P. J. Lucassen, J. Pruessner, N. Sousa et al., “Neuropathology of
stress,” Acta Neuropathologica, vol. 127, no. 1, pp. 109–135, 2014.
[3] B. S. McEwen, L. Eiland, R. G. Hunter, andM.M.Miller, “Stress
and anxiety: structural plasticity and epigenetic regulation as a
consequence of stress,” Neuropharmacology, vol. 62, no. 1, pp.
3–12, 2012.
[4] M. A. Mehta, N. I. Golembo, C. Nosarti et al., “Amygdala, hip-
pocampal and corpus callosum size following severe early
institutional deprivation: the English and Romanian Adoptees
study pilot.,” Journal of Child Psychology and Psychiatry, and
Allied Disciplines, vol. 50, no. 8, pp. 943–951, 2009.
[5] T. Frodl and V. O’Keane, “How does the brain deal with cumu-
lative stress? A review with focus on developmental stress, HPA
axis function and hippocampal structure in humans,” Neurobi-
ology of Disease, vol. 52, pp. 24–37, 2013.
[6] B. Cze´h, N. Abumaria, R. Rygula, and E. Fuchs, “Quantita-
tive changes in hippocampal microvasculature of chronically
stressed rats: no effect of fluoxetine treatment,” Hippocampus,
vol. 20, no. 1, pp. 174–185, 2010.
[7] V. H. Shende, C. R. Pryce, D. Ru¨edi-Bettschen, T. C. Rae, and
J. Opacka-Juffry, “Evidence for hippocampal remodeling as a
long term effect of early life stress in the rat model of early
deprivation,” Recent Developments in Brain Research, vol. 1, pp.
1–19, 2012.
[8] A. Jackowski, T. D. Perera, C. G. Abdallah et al., “Early-life
stress, corpus callosum development, hippocampal volumet-
rics, and anxious behavior in male nonhuman primates,” Psy-
chiatry Research—Neuroimaging, vol. 192, no. 1, pp. 37–44, 2011.
[9] C. Pittenger and R. S. Duman, “Stress, depression, and neuro-
plasticity: a convergence of mechanisms,”Neuropsychopharma-
cology, vol. 33, no. 1, pp. 88–109, 2008.
[10] C. L. Coe, M. Kramer, B. Cze´h et al., “Prenatal stress diminishes
neurogenesis in the dentate gyrus of juvenile Rhesus monkeys,”
Biological Psychiatry, vol. 54, no. 10, pp. 1025–1034, 2003.
[11] J. D. Funkhouser, K. J. Peevey, P. B. Mockridge, and E. R.
Hughes, “Distribution of dexamethasone between mother and
fetus after maternal administration,” Pediatric Research, vol. 12,
no. 11, pp. 1053–1056, 1978.
[12] D. Roberts and S. Dalziel, “Antenatal corticosteroids for accel-
erating fetal lung maturation for women at risk of preterm
birth,” Cochrane Database of Systematic Reviews, vol. 3, Article
ID CD004454, 2006.
[13] T. F. Yeh, Y. J. Lin, H. C. Lin et al., “Outcomes at school age
after postnatal dexamethasone therapy for lung disease of pre-
maturity,”TheNew England Journal of Medicine, vol. 350, no. 13,
pp. 1304–1313, 2004.
[14] J. P. Empana, M. M. Anceschi, I. Szabo, E. V. Cosmi, G. Breart,
and P. Truffert, “Antenatal corticosteroids policies in 14 Euro-
pean countries: factors associated with multiple courses. The
EURAIL survey,” Acta Paediatrica, International Journal of Pae-
diatrics, vol. 93, no. 10, pp. 1318–1322, 2004.
[15] C. Romagnoli, E. Zecca, R. Luciano, G. Torrioli, and G. Tor-
torolo, “A three year follow up of preterm infants after moder-
ately early treatment with dexamethasone,” Archives of Disease
in Childhood: Fetal and Neonatal Edition, vol. 87, no. 1, pp. F55–
F58, 2002.
[16] A. Charil, D. P. Laplante, C. Vaillancourt, and S. King, “Prenatal
stress and brain development,” Brain Research Reviews, vol. 65,
no. 1, pp. 56–79, 2010.
[17] D. Tijsseling, L. D. E. Wijnberger, J. B. Derks et al., “Effects of
antenatal glucocorticoid therapy on hippocampal histology of
preterm infants,”PLoSONE, vol. 7, no. 3, Article ID e33369, 2012.
[18] C. W. Noorlander, D. Tijsseling, E. V. S. Hessel et al., “Antenatal
glucocorticoid treatment affects hippocampal development in
mice,” PLoS ONE, vol. 9, no. 1, Article ID e85671, 2014.
[19] S. McArthur, E. McHale, and G. E. Gillies, “The size and distri-
bution of midbrain dopaminergic populations are permanently
altered by perinatal glucocorticoid exposure in a sex- region-
and time-specific manner,” Neuropsychopharmacology, vol. 32,
no. 7, pp. 1462–1476, 2007.
[20] S. McArthur, E. McHale, J. W. Dalley, J. C. Buckingham, and
G. E. Gillies, “Alteredmesencephalic dopaminergic populations
in adulthood as a consequence of brief perinatal glucocorticoid
exposure,” Journal of Neuroendocrinology, vol. 17, no. 8, pp. 475–
482, 2005.
[21] E.Theogaraj, C.D. John,H. C. Christian, J. F.Morris, S. F. Smith,
and J. C. Buckingham, “Perinatal glucocorticoid treatment
produces molecular, functional, and morphological changes in
the anterior pituitary gland of the adultmale rat,”Endocrinology,
vol. 146, no. 11, pp. 4804–4813, 2005.
[22] G. Paxinos and C. Watson,The Rat Brain in Stereotaxic Coordi-
nates, Elsevier Academic Press, 5th edition, 2005.
[23] M. Leventopoulos, D. Ru¨edi-Bettschen, I. Knuesel, J. Feldon, C.
R. Pryce, and J. Opacka-Juffry, “Long-term effects of early life
deprivation on brain glia in Fischer rats,” Brain Research, vol.
1142, no. 1, pp. 119–126, 2007.
[24] M. J. West, L. Slomianka, and H. J. G. Gundersen, “Unbiased
stereological estimation of the total number of neurons in
8 Neural Plasticity
the subdivisions of the rat hippocampus using the optical frac-
tionator,” Anatomical Record, vol. 231, no. 4, pp. 482–497, 1991.
[25] D. T. Theodosis, D. A. Poulain, and S. H. R. Oliet, “Activity-
dependent structural and functional plasticity of astrocyte-
neuron interactions,” Physiological Reviews, vol. 88, no. 3, pp.
983–1008, 2008.
[26] H. Uno, L. Lohmiller, C. Thieme et al., “Brain damage induced
by prenatal exposure to dexamethasone in fetal rhesus maca-
ques. I. Hippocampus,” Developmental Brain Research, vol. 53,
no. 2, pp. 157–167, 1990.
[27] R. Q. Carlos, F. J. Seidler, and T. A. Slotkin, “Fetal dexametha-
sone exposure altersmacromolecular characteristics of rat brain
development: a critical period for regionally selective altera-
tions?” Teratology, vol. 46, no. 1, pp. 45–59, 1992.
[28] E. R. de Kloet, “Stress in the brain,” European Journal of Phar-
macology, vol. 405, pp. 187–198, 2000.
[29] S. G. Matthews, “Antenatal glucocorticoids and the developing
brain: mechanisms of action,” Seminars in Neonatology, vol. 6,
no. 4, pp. 309–317, 2001.
[30] L. J. Abernethy, M. Palaniappan, and R. W. I. Cooke, “Quanti-
tative magnetic resonance imaging of the brain in survivors of
very low birth weight,” Archives of Disease in Childhood, vol. 87,
no. 4, pp. 279–283, 2002.
[31] E. B. Isaacs, A. Lucas,W. K. Chong et al., “Hippocampal volume
and everyday memory in children of very low birth weight,”
Pediatric Research, vol. 47, no. 6, pp. 713–720, 2000.
[32] B. S. Peterson, B. Vohr, L. H. Staib et al., “Regional brain volume
abnormalities and long-term cognitive outcome in preterm
infants,” Journal of the American Medical Association, vol. 284,
no. 15, pp. 1939–1947, 2000.
[33] B. P. Murphy, T. E. Inder, P. S. Huppi et al., “Impaired cerebral
cortical graymatter growth after treatmentwith dexamethasone
for neonatal chronic lung disease,” Pediatrics, vol. 107, no. 2, pp.
217–221, 2001.
[34] P. Yossuck, M. Kraszpulski, and A. K. Salm, “Perinatal corti-
costeroid effect on amygdala and hippocampus volume during
brain development in the rat model,” Early Human Develop-
ment, vol. 82, no. 4, pp. 267–272, 2006.
[35] D. Rice and S. Barone Jr., “Critical periods of vulnerability for
the developing nervous system: evidence from humans and
animal models,” Environmental Health Perspectives, vol. 108, no.
3, pp. 511–533, 2000.
[36] C. S. Woolley, E. Gould, and B. S. McEwen, “Exposure to
excess glucocorticoids alters dendritic morphology of adult
hippocampal pyramidal neurons,” Brain Research, vol. 531, no.
1-2, pp. 225–231, 1990.
[37] R. M. Sapolsky, H. Uno, C. S. Rebert, and C. E. Finch, “Hippo-
campal damage associatedwith prolonged glucocorticoid expo-
sure in primates,”The Journal of Neuroscience, vol. 10, no. 9, pp.
2897–2902, 1990.
[38] F. Ohl, T. Michaelis, G. K. Vollmann-Honsdorf, C. Kirschbaum,
and E. Fuchs, “Effect of chronic psychosocial stress and long-
term cortisol treatment on hippocampus-mediated memory
and hippocampal volume: a pilot-study in tree shrews,” Psy-
choneuroendocrinology, vol. 25, no. 4, pp. 357–363, 2000.
[39] C. Nosarti, M. H. S. Al-Asady, S. Frangou, A. L. Stewart, L. Rif-
kin, and R. M. Murray, “Adolescents who were born very pre-
term have decreased brain volumes,” Brain, vol. 125, no. 7, pp.
1616–1623, 2002.
[40] L. E. Haynes, M. R. Griffiths, R. E. Hyde, D. J. Barber, and I. J.
Mitchell, “Dexamethasone induces limited apoptosis and exten-
sive sublethal damage to specific subregions of the striatum and
hippocampus: implications for mood disorders,” Neuroscience,
vol. 104, no. 1, pp. 57–69, 2001.
[41] N. Sousa, M. M. Paula-Barbosa, and O. F. X. Almeida, “Ligand
and subfield specificity of corticoid-induced neuronal loss in
the rat hippocampal formation,”Neuroscience, vol. 89, no. 4, pp.
1079–1087, 1999.
[42] K. L. Crossin, M.-H. Tai, L. A. Krushel, V. P. Mauro, and G. M.
Edelman, “Glucocorticoid receptor pathways are involved in the
inhibition of astrocyte proliferation,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 94, no.
6, pp. 2687–2692, 1997.
[43] M. Sabolek, A. Herborg, J. Schwarz, and A. Storch, “Dexam-
ethasone blocks astroglial differentiation from neural precursor
cells,” NeuroReport, vol. 17, no. 16, pp. 1719–1723, 2006.
[44] N. R. Nichols, J. N. Masters, and C. E. Finch, “Changes in gene
expression in hippocampus in response to glucocorticoids and
stress,” Brain Research Bulletin, vol. 24, no. 5, pp. 659–662, 1990.
[45] N. R. Nichols, H. H. Osterburg, J. N. Masters, S. L. Millar,
and C. E. Finch, “Messenger RNA for glial fibrillary acidic
protein is decreased in rat brain following acute and chronic
corticosterone treatment,” Molecular Brain Research, vol. 7, no.
1, pp. 1–7, 1990.
[46] N. J. Laping, N. R. Nichols, J. R. Day, and C. E. Finch, “Cortico-
sterone differentially regulates the bilateral response of astro-
cyte mRNAs in the hippocampus to entorhinal cortex lesions in
male rats,”Molecular Brain Research, vol. 10, no. 4, pp. 291–297,
1991.
[47] S. Tsuneishi, S. Takada, T. Motoike, T. Ohashi, K. Sano, and
H. Nakamura, “Effects of dexamethasone on the expression of
myelin basic protein, proteolipid protein, and glial fibrillary
acidic protein genes in developing rat brain,” Developmental
Brain Research, vol. 61, no. 1, pp. 117–123, 1991.
[48] J. P. O’Callaghan, R. E. Brinton, and B. S. McEwen, “Glucocor-
ticoids regulate the synthesis of glial fibrillary acidic protein in
intact and adrenalectomized rats but do not affect its expression
following brain injury,” Journal of Neurochemistry, vol. 57, no. 3,
pp. 860–869, 1991.
[49] M. V. Sofroniew and H. V. Vinters, “Astrocytes: biology and
pathology,”Acta Neuropathologica, vol. 119, no. 1, pp. 7–35, 2010.
[50] S. Maccari, M. Darnaudery, S. Morley-Fletcher, A. R. Zuena, C.
Cinque, and O. van Reeth, “Prenatal stress and long-term
consequences: implications of glucocorticoid hormones,” Neu-
roscience and Biobehavioral Reviews, vol. 27, no. 1-2, pp. 119–127,
2003.
[51] C. R. Pryce, Y. Aubert, C.Maier, P. C. Pearce, and E. Fuchs, “The
developmental impact of prenatal stress, prenatal dexametha-
sone and postnatal social stress on physiology, behaviour and
neuroanatomy of primate offspring: Studies in rhesus macaque
and common marmoset,” Psychopharmacology, vol. 214, no. 1,
pp. 33–53, 2011.
